WHAT IS CLAIMED IS:

- 1. A topical medicament intended for stopping bleeding, closing a wound, or promoting wound healing in a subject in need of such treatment, comprising the following active agents in therapeutic amounts:
 - (i) an agent selected from the group consisting of fibrinogen and fibrin;
 - (ii) thrombin;
 - (iii) a transglutaminase; and
- (iv) a serpin protease inhibitor which does not inhibit collagenase and elastase; wherein the active agents may be obtained from a source selected from the group of allogenic plasma, allogenic tissue, and recombinant production; and wherein an active substance of allogenic origin is subjected to a process selected from the group consisting of virus depletion, virus inactivation and a combination thereof; provided that where such a process is applied to the serpin protease inhibitor, it is not applied in the presence of one or more of the other active agents.
- 2. The medicament of claim 1, further comprising allogenic collagens subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 3. The medicament of claim 1, further comprising one or more allogenic active agent selected from the group consisting of fibronectin, vitronectin, thrombospondin, tenascin, laminin and proteoglycans, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 4. The medicament of claim 2, further comprising one or more allogenic active agent selected from the group consisting of fibronectin, vitronectin, thrombospondin, tenascin, laminin and proteoglycans, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 5. The medicament of claim 1, further comprising one or more allogenic active agent selected from the group consisting of growth factors,



chemotactic substancs, cell stimulating enzymes, cell proliferation enhancing enzymes, inhibitors of cell stimulating enzymes, inhibitors of cell proliferation enhancing enzymes, cell proliferation inhibiting enzymes, inhibitors of cell proliferation inhibiting enzymes, cytokines, and particulately formed cell elements, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

- 6. The medicament of claim 2, further comprising one or more allogenic active agent selected from the group consisting of growth factors, chemotactic substancs, cell stimulating enzymes, cell proliferation enhancing enzymes, inhibitors of cell stimulating enzymes, inhibitors of cell proliferation enhancing enzymes, cell proliferation inhibiting enzymes, inhibitors of cell proliferation inhibiting enzymes, cytokines, and particulately formed cell elements, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 7. The medicament of claim 3, further comprising one or more allogenic active agent selected from the group consisting of growth factors, chemotactic substancs, cell stimulating enzymes, cell proliferation enhancing enzymes, inhibitors of cell stimulating enzymes, inhibitors of cell proliferation enhancing enzymes, cell proliferation inhibiting enzymes, inhibitors of cell proliferation inhibiting enzymes, cytokines, and particulately formed cell elements, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 8. The medicament of claim 4, further comprising one or more allogenic active agent selected from the group consisting of growth factors, chemotactic substancs, cell stimulating enzymes, cell proliferation enhancing enzymes, inhibitors of cell stimulating enzymes, inhibitors of cell proliferation enhancing enzymes, cell proliferation inhibiting enzymes, inhibitors of cell proliferation inhibiting enzymes, cytokines, and particulately formed cell elements, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

- 9. The medicament of claim 1, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 10. The medicament of claim 2, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 11. The medicament of claim 3, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 12. The medicament of claim 4, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 13. The medicament of claim 5, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 14. The medicament of claim 6, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active

agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

- 15. The medicament of claim 7, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 16. The medicament of claim 8, further comprising one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 17. The medicament of claim 1, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 18. The medicament of claim 2, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 19. The medicament of claim 3, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 20. The medicament of claim 4, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.

- 21. The medicament of claim 5, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 22. The medicament of claim 6, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 23. The medicament of claim 7, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 24. The medicament of claim 8, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 25. The medicament of claim 9, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 26. The medicament of claim 10, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 27. The medicament of claim 11, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic


agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.

- 28. The medicament of claim 12, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 29. The medicament of claim 13, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 30. The medicament of claim 14, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 31. The medicament of claim 15, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 32. The medicament of claim 16, further comprising one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.
- 33. The medicament of claim 1, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

- 34. The medicament of claim 2, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 35. The medicament of claim 3, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 36. The medicament of claim 4, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 37. The medicament of claim 5, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 38. The medicament of claim 6, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 39. The medicament of claim 7, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active

agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.


- 40. The medicament of claim 8, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 41. The medicament of claim 9, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 42. The medicament of claim 10, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 43. The medicament of claim 11, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 44. The medicament of claim 12, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.



- 45. The medicament of claim 13, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 46. The medicament of claim 14, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 47. The medicament of claim 15, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 48. The medicament of claim 16, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 49. The medicament of claim 17, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 50. The medicament of claim 18, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active

agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

- 51. The medicament of claim 19, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 52. The medicament of claim 20, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 53. The medicament of claim 21, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 54. The medicament of claim 22, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 55. The medicament of claim 23, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.



- 56. The medicament of claim 24, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 57. The medicament of claim 25, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 58. The medicament of claim 26, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 59. The medicament of claim 27, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 60. The medicament of claim 28, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 61. The medicament of claim 29, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active

٥

agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.


- 62. The medicament of claim 30, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 63. The medicament of claim 31, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 64. The medicament of claim32, further comprising one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 65. The medicament of claim 1, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 66. The medicament of claim 2, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group

consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.

- 67. The medicament of claim 5, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 68. The medicament of claim 6, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 69. The medicament of claim 9, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 70. The medicament of claim 10, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.


- 71. The medicament of claim 13, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 72. The medicament of claim 14, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 73. The medicament of claim 17, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 74. The medicament of claim 18, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.

- 75. The medicament of claim 21, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 76. The medicament of claim 22, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 77. The medicament of claim 25, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 78. The medicament of claim 26, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 79. The medicament of claim 29, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate



cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.


- 80. The medicament of claim 30, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 81. The medicament of claim 31, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 82. The medicament of claim 33, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 83. The medicament of claim 34, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations



thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.

- 84. The medicament of claim 37, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 85. The medicament of claim 38, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 86. The medicament of claim 41, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 87. The medicament of claim 42, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group

o



consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.


- 88. The medicament of claim 45, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 89. The medicament of claim 46, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 90. The medicament of claim 49, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 91. The medicament of claim 50, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.

A34720-PCT-USA-A

- 92. The medicament of claim 53, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 93. The medicament of claim 54, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 94. The medicament of claim 57, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 95. The medicament of claim 58, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.



- 96. The medicament of claim 61, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 97. The medicament of claim 62, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 98. The medicament of claim 63, further comprising an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.
- 99. The medicament of claim 1, wherein all of the active substances are present as an allogenic provisional extracellular matrix in a single pharmaceutical preparation.
- 100. The medicament of claim 1, wherein the active substances are present in separate pharmaceutical preparations to be mixed prior to or during application, wherein the mixture obtained may be applied in a form selected from the group consisting of liquid form and solid form.



- 101. The medicament of claim 100, wherein fibrinogen and thrombin are each present in a separate pharmaceutical preparation and the remaining active substances, independent of one another, are contained in either the fibrinogen-containing preparation, the thrombin-containing preparation, or another pharmaceutical preparation.
- 102. The medicament of claim 1, wherein one or more of the active agents are applied on carrier materials subjected to a process selected from the group of virus depletion, virus inactivation, and a combination thereof.
- 103. The medicament of claim 1, wherein the medicament is solidified into an allogenic provisional extracellular matrix by a means selected from the group consisting of the application of pressure and the use of dehydrating agents.
- 104. The medicament of claim 103, wherein the allogenic provisional matrix is solidified by the use of dehydrating agents and treated with allogenic transglutaminases.
- 105. A process for preparing a fibrinogen-containing solution which is storable at refrigerator temperature or room temperature, comprising a step selected from the group consisting of preparing fibrinogen recombinantly and purifying fibrinogen from plasma by fractionation with glycine at a temperature equal to or less than zero degrees Celsius.
- 106. The process of claim 105, wherein the solution further comprises fibronectin.
- 107. A medicament comprising a highly purified fibrinogen-containing preparation having (i) an aPTT, measured at 37°C, of at least 200 seconds; (ii) a taipan viper venom prothrombin time, measured at 37°C, of at least 300 seconds; and (iii) a stability that permits its storage for more than two years at a temperature of 4° 8°C without the formation of an insoluble fibrin precipitate or the formation of fibrinogen cleavage products.



- 108. A medicament comprising a highly purified fibrinogen-fibronectin- containing preparation having (i) an aPTT, measured at 37°C, of at least 200 seconds; (ii) a taipan viper venom prothrombin time, measured at 37°C, of at least 300 seconds; and (iii) a stability that permits its storage for more than two years at a temperature of 4° 8°C without the formation of an insoluble fibrin precipitate or the formation of fibrinogen cleavage products.
- 109. A process for obtaining a pathogen-free active substance comprising (i) depleting virus in the substance by a process selected from the group consisting of ultracentrifugation, ultrafiltration, nanofiltration, adsorption, and combinations thereof, where the process is carried out a temperature below zero degrees Celsius; and (ii)inactivating virus in the substance by subjecting the substance to at least two of the processes in the group consisting of heat pulse processes carried out for less than three seconds, intensive laser pulse radiation, and exposure to detergents in the presence of hydrophobic wetting agents.
- 110. A process for covalently binding an active agent to a biological matrix comprising catalyzing the binding reaction with an allogenic transglutaminase at a concentration more than ten-fold greater than the concentration of activated factor XIIIa zymogen in plasma, wherein the transglutaminase has been treated with a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.
- 111. A process for preparing a fibrin-containing gel having a water content between 20 and 90 percent, comprising preparing a fibrin containing gel and then exposing the gel to an atoxic, pharmaceutically suitable dehydrating agent.
- 112. The process of claim 111, wherein the dehydrating agent is polyethylene glycol.
- 113. A process for preparing a fibrin-containing gel having a water content of between 20 and 90 percent, comprising preparing a fibrin-containing gel and then removing water from the gel by applying pressure, wherein the pressure is increased gradually to avoid destroying the gel.

- 114. The process of claim 111, further comprising the step of exposing the gel to a transglutaminase.
- 115. The process of claim 112, further comprising the step of exposing the gel to a transglutaminase.

114. The process of claim 113, further comprising the step of exposing the gel to a transglutaminase.

// 175. A process for solidifying a fibrin-containing gel, comprising preparing a fibrin-containing gel and then placing the gel in a solution containing metallic ions.

1/8 116. The process of claim 115 wherein the solution contains zinc and aluminum ions at concentrations between 0.01 to 2 molar.

1918. A lyophilized fibrin-containing gel prepared by a process comprising the steps of adding a plasticizer to the gel prior to its solidification and lyophilization.

120 118. The gel of claim 117, wherein the plasticizer is glycol.

A process for preparing a highly viscous fibrinogen-containing solution, comprising the step of mixing (a) a fibrinogen solution which has been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof with (b) a thrombin solution which has been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof, wherein the relative amounts of fibrinogen to thrombin are one gram of fibrinogen to between 0.01 and 0.1 units of thrombin.

wound bed, comprising the steps of (i) forming a fibrin clot using increasing amounts of protease inhibitors on the surface of a tissue culture; (ii) rendering the clot

Ď.

detectable by exposing the clot to a detection agent selected from the group consisting of staining substances and water-insoluble substances; (iii) subjecting the tissue culture to a shaking or rotating motion; and (iv) determining the time after which the fibrin clot detaches from the surface of the tissue culture.

123121. A method of treating a wound of a subject, comprising applying, to the wound, a topical medicament comprising the following active agents in therapeutic amounts:

- (i) an agent selected from the group consisting of fibrinogen and fibrin;
- (ii) thrombin;
- (iii) a transglutaminase; and
- (iv) a serpin protease inhibitor which does not inhibit collagenase and elastase; wherein the active agents may be obtained from a source selected from the group of allogenic plasma, allogenic tissue, and recombinant production; and wherein an active substance of allogenic origin is subjected to a process selected from the group consisting of virus depletion, virus inactivation and a combination thereof; provided that where such a process is applied to the serpin protease inhibitor, it is not applied in the presence of one or more of the other active agents.

124 122. The method of claim 121, wherein the medicament further comprises allogenic collagens subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

123. The method of claim 121, wherein the medicament further comprises one or more allogenic active agent selected from the group consisting of fibronectin, vitronectin, thrombospondin, tenascin, laminin and proteoglycans, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

23 24. The method of claim 121, wherein the medicament further comprises one or more allogenic active agent selected from the group consisting of growth factors, chemotactic substancs, cell stimulating enzymes, cell proliferation enhancing enzymes, inhibitors of cell stimulating enzymes, inhibitors of cell proliferation enhancing enzymes, cell proliferation inhibiting enzymes, inhibitors of



cell proliferation inhibiting enzymes, cytokines, and particulately formed cell elements, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

123. The method of claim 121, wherein the medicament further comprises one or more active agent selected from the group consisting of allogenic plasmatic enzymes, enzymes obtained from tissues, zymogens, and enzyme inhibitors, wherein the allogenic active agent is subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

126. The method of claim 121, wherein the medicament further comprises one or more active agent selected from the group consisting of antiadherent agents, antiphlogistic agents, antimicrobial agents, cytostatic agents, active substances that are absorbed slowly, and combinations thereof.

121. The method of claim 121, wherein the medicament further comprises one or more allogenic active agents selected from the group consisting of zymogens of the coagulation cascade and enzymes of the coagulation cascade, wherein said active agents have been subjected to a process selected from the group consisting of virus depletion, virus inactivation, and a combination thereof.

20128. The method of claim 121, wherein the medicament further comprises an allogenic component selected from the group consisting of particulate cell elements, particulate cell elements applied on virus-safe microspheres, cells, cells applied on virus-safe microspheres, tissues, tissues applied on virus-safe microspheres, and combinations thereof, wherein the microspheres may consist of a substrate selected from the group consisting of allogenic fibrin, allogenic collagen, allogenic collagen plus allogenic fibrin, and combinations thereof.